Clinical Haematology

Department of Clinical Haematology

The Clinical Haematology Department at the Canberra Region Cancer Centre provides a regional comprehensive multidisciplinary service for the diagnosis and treatment of all types of haematological disorders including:

  • Malignant diseases, e.g. leukaemia, lymphoma and multiple myeloma.
  • Immunological diseases affecting the blood causing reduction in any blood cells, e.g. immune thrombocytopenia (ITP), thrombotic thrombocytopenic purpura (TTP) and aplastic anaemia.
  • Hereditary blood cell problems, e.g. thalassaemia, sickle cell disorders, red cell membrane abnormalities.
  • Clotting problems, e.g. abnormal bleeding or bruising, haemophilia, tendency to form clots (thrombophilia).
  • Other non-malignant diseases, e.g. anaemia, low platelet or neutrophil counts.

In addition to dealing with these diseases, the department also provides a number of other services, including:

  • Autologous stem cell transplants
  • Therapeutic apheresis (removal of blood cells or plasma proteins mechanically).
  • Immunology for rare diseases, e.g. paroxysmal nocturnal  haemoglobinaemia (using specially designed antibodies)
  • Management of iron overload
  • Haematology clinical trials

Haematology services are provided mainly from the following locations:

  • Ward 14B at the Canberra Hospital for inpatient care
  • Outpatient clinic on Level 2 of the Canberra Region Cancer Centre.
  • Day-chemotherapy on Level 4 of the Canberra Region Cancer Centre.
  • Cancer Outreach Team on Level 4 of the Canberra Region Cancer Centre.
  • Apheresis service on Level 4 of the Canberra Region Cancer Centre.

As a tertiary centre within a teaching hospital, the unit is accredited by the Royal Australasian College of Physicians (RACP) and Royal College of Pathologists of Australasia (RCPA) for general and specialist training. It also has an active clinical trials unit and a tissue bank (in collaboration with the pathology department) to support research.

Refer a patient

Patients must have a valid referral from their general practitioner or from another specialist.

Referrals can be faxed to: Haematology (02) 6174 5544

Find a specialist

All our specialists have interest in general haematological conditions, as well as service commitments in the haematology laboratory and teaching commitments at the Australian National University (ANU). In addition, all have their own special interest and academic commitments as indicated below.

  • Dr James D'Rozario MBBS, FRACP, FRCPA
    Clinical Director, Haematology.
    Special interests: Leukaemia, Lymphoma and stem cell transplant, medical education.
  • Dr Philip Choi BA BSc(Med) MBBS PhD FRACP FRCPA
    Haematologist
    Special interests: Thrombocytopenia, thrombotic disorders and autoimmune disease in Haematology.
    Additional languages spoken: Korean
  • Dr Philip Crispin MBBS. FRACP, FRCPA
    Haematologist
    Special interests: Transfusion medicine, coagulation
  • Dr Maya Latimer MMBS, FRACP, FRCPA
    Haematologist
    Special interests: Leukaemia, Lymphoma, Myeloma, medical education.
  • Dr Edwin Lee MBChB MD, FRCP, FRCPath, FRACP
    Haematologist
    Special interests: Leukaemia, Myeloma, Amyloidosis, myeloproliferative neoplasm, clotting disorders.
  • Dr Nalini Pati MBBS, DCH, MD, DNB, FRACP, FRCPA
    Haematologist
    Special interests: Leukaemia, Lymphoma, Myeloma, bleeding disorders, stem cell transplant, paediatric haematology
  • Dr Emma Palfreyman MBBS (Hons), FRACP, FRCPA
    Haematologist
    Special interests: Leukaemia Lymphoma, bone marrow failure syndromes and stem cell transplant.
  • Dr Michael Pidcock MBBS, FRACP, FRCPA, FRCP
    Haematologist
    Special interests: Lymphoma, chronic leukaemia, bleeding disorders, haemoglobin disorders.
  • Dr Dipti Talaulikar MBBS, PhD, FRACP, FRCPA
    Haematologist
    Special interests: Lymphoma, Myeloma, Myeloproliferative neoplasm, medical education and research.
  • ​Kathlene Robson
    Clinical Nurse Consultant

Clinical Trials

The Clinical Haematology Department is active in local, national and international trials and data registries. As clinical trials are opened and closed all the time, a sample list of these trials is provided below for reference only.

An up-to-date list can be viewed using the ClinTrialRefer App available on the iOS and Android platforms, downloadable via the internet.

If you are interested in participating in any clinical trials, please ask your haematology specialist for more information.

  • ADMYRE - Diagnosis: Myeloma. Patient Eligibility: Relapsed / refractory myeloma
  • ALLG ALL06 - Diagnosis: Acute lymphoblastic leukaemia. Patient eligibility: Newly diagnosed acute myeloid leukaemia with FLT-3 mutation.
  • ALLG AMLM18 - Diagnosis: Acute myeloid leukaemia. Patient eligibility: Registry study. Any newly diagnosed patient with acute myeloid leukaemia.
  • ALLG AMLM16 - Diagnosis: Acute myeloid leukaemia. Patient eligibility: Newly diagnosed acute myeloid leukaemia.
  • ALLG CLL6 RESIDUUM - Diagnosis: Chronic lymphocytic leukaemia. Patient eligibility: Recently completed fludarabine-based chemotherapy.
  • ALLG MM14 - Diagnosis: Multiple myeloma. Patient eligibility: Relapsed/refractory myeloma.
  • AMBIT AC-220-007 - Diagnosis: Acute myeloid leukaemia. Patient Eligibility: Relapsed/refractory acute myeloid leukaemia with a specific mutation (FLT3-ITD) in the leukaemic cells.
  • Bay 16349 - Diagnosis: Follicular non-Hodgkin's lymphoma (NHL). Patient Eligibility: Relapsed/refractory follicular NHL after at least 2 lines of treatment.
  • BI695500 - Diagnosis: Follicular NHL. Patient Eligibility: Previously untreated stage II to IV follicular NHL.
  • MURANO (GO28667) - Diagnosis: Chronic lymphocytic leukaemia. Patient Eligibility: Relapsed/refractory chronic lymphocytic leukaemia at least 6 months from previous chemotherapy.
  • ROBIN - Diagnosis: Indolent NHL. Patient Eligibility: Indolent NHL refractory to previous rituximab-containing treatments.

Other support services alegall@leukaemia.org.au

or the Leukaemia Foundation

Translational Research

The Clinical Haematology Department is closely linked with the John Curtin School of Medical Research at the Australian National University and collaborate in a number of research projects.

Examples of these are:

PROJECT: Dichloroacetate in the treatment of multiple myeloma.
INVESTIGATOR / COLLABORATOR: Dr Anneke Blackburn, The John Curtin School of Medical Research.
Further information

PROJECT: Lymphoma cell origin and association with autoimmune diseases.
INVESTIGATOR / COLLABORATOR: Dr Dipti Talaulikar, TCH.
Further information

PROJECT: Research Tissue Bank.
INVESTIGATOR / COLLABORATOR: Dr Dipti Talaulikar TCH.
Further information

Teaching and Training

The Department has a strong commitment in providing general physician and specialist haematology training. Apart from on-the-job learning, there are structured teaching program trainees at all levels.

See haematology training for more details.